UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 158

Sortiert nach

Structure-Based Discovery of Novel Ligands for the Orexin 2 Receptor

Journal of medicinal chemistry, 2020-10, Vol.63 (19), p.11045-11053

2020

Link zum Volltext

Verfügbarkeit prüfen

Comparative Docking to Distinct G Protein-Coupled Receptor Conformations Exclusively Yields Ligands with Agonist Efficacy

Molecular pharmacology, 2019-12, Vol.96 (6), p.851-861

2019

Link zum Volltext

Verfügbarkeit prüfen

EP4 Receptor Conformation Sensor Suited for Ligand Screening and Imaging of Extracellular Prostaglandins

Molecular pharmacology, 2023-09, Vol.104 (3), p.80

2023

Link zum Volltext

Verfügbarkeit prüfen

The Isoleucine at Position 118 in Transmembrane 2 Is Responsible for the Selectivity of Xamoterol, Nebivolol, and ICI89406 for the Human β 1-Adrenoceptor

Molecular pharmacology, 2023-02, Vol.103 (2), p.89-99

2023

Link zum Volltext

Verfügbarkeit prüfen

Three stories on Eph kinase inhibitors: From in silico discovery to in vivo validation

European journal of medicinal chemistry, 2016-04, Vol.112, p.347-366

2016

Link zum Volltext

Verfügbarkeit prüfen

Structure-based tailoring of compound libraries for high-throughput screening: Discovery of novel EphB4 kinase inhibitors

Proteins, structure, function, and bioinformatics, 2008-10, Vol.73 (1), p.11-18

2008

Link zum Volltext

Verfügbarkeit prüfen

Disentangling bias between G q , GRK2, and arrestin3 recruitment to the M 3 muscarinic acetylcholine receptor

eLife, 2021-12, Vol.10

2021

Link zum Volltext

Verfügbarkeit prüfen

Discovery of Cell-Permeable Non-Peptide Inhibitors of β-Secretase by High-Throughput Docking and Continuum Electrostatics Calculations

Journal of medicinal chemistry, 2005-08, Vol.48 (16), p.5108-5111

2005

Link zum Volltext

Verfügbarkeit prüfen

Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma

PloS one, 2014-08, Vol.9 (8), p.e106249

2014

Link zum Volltext

Verfügbarkeit prüfen

The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models

Clinical cancer research, 2021-05, Vol.27 (10), p.2938-2946

2021

Link zum Volltext

Verfügbarkeit prüfen

Smad3-dependent and -independent pathways are involved in peritoneal membrane injury

Kidney international, 2010-02, Vol.77 (4), p.319-328

2010

Link zum Volltext

Verfügbarkeit prüfen

Defective DNA damage repair leads to frequent catastrophic genomic events in murine and human tumors

Nature communications, 2018-11, Vol.9 (1), p.4760-13, Article 4760

2018

Link zum Volltext

Verfügbarkeit prüfen

Plant fertilization interacts with life history: variation in stoichiometry and performance in nettle-feeding butterflies

PloS one, 2015-05, Vol.10 (5), p.e0124616-e0124616

2015

Link zum Volltext

Verfügbarkeit prüfen

PNPLA1 Deficiency in Mice and Humans Leads to a Defect in the Synthesis of Omega-O-Acylceramides

Journal of investigative dermatology, 2017-02, Vol.137 (2), p.394-402

2017

Link zum Volltext

Verfügbarkeit prüfen

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program

Pediatric Blood & Cancer, 2008-06, Vol.50 (6), p.1190-1197

2008

Link zum Volltext

Verfügbarkeit prüfen

Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report

Pediatric blood & cancer, 2020-05, Vol.67 (5), p.e28098-n/a

2020

Link zum Volltext

Verfügbarkeit prüfen

Ecological stoichiometry and density responses of plant-arthropod communities on cormorant nesting islands

PloS one, 2013-04, Vol.8 (4), p.e61772-e61772

2013

Link zum Volltext

Verfügbarkeit prüfen

The pediatric preclinical testing program: Description of models and early testing results

Pediatric blood & cancer, 2007-12, Vol.49 (7), p.928-940

2007

Link zum Volltext

Verfügbarkeit prüfen

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673

Pediatric blood & cancer, 2015-01, Vol.62 (1), p.91-98

2015

Link zum Volltext

Verfügbarkeit prüfen

Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program

Clinical cancer research, 2015-02, Vol.21 (4), p.819-832

2015

Link zum Volltext

Verfügbarkeit prüfen

VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats

The Journal of clinical investigation, 2009-05, Vol.119 (5), p.1298-1311

2009

Link zum Volltext

Verfügbarkeit prüfen

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

Pediatric blood & cancer, 2013-08, Vol.60 (8), p.1325-1332

2013

Link zum Volltext

Verfügbarkeit prüfen

Dose‐response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium

Pediatric blood & cancer, 2020-10, Vol.67 (10), p.e28606-n/a

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 158

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieAmerican Journal Of Respiratory And Critical Care Medicine

ThemaAnimals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(155)
Mit Volltextzugriff
(145)

Publikationsform

Artikel
(158)

Sprache

Englisch
(158)
Japanisch
(39)

Erscheinungsjahr

n.n

Thema

Science & Technology
(143)
Life Sciences & Biomedicine
(136)
Humans
(107)
Mice
(95)
Female
(77)
Oncology
(73)
Pediatrics
(65)
Hematology
(64)
Xenograft Model Antitumor Assays
(64)
Preclinical Testing
(62)
Developmental Therapeutics
(61)
Cell Line, Tumor
(49)
Mice, Scid
(45)
Mice, Inbred Balb C
(33)
Child
(32)
Antineoplastic Agents - Pharmacology
(27)
Rats
(25)
Neoplasms, Experimental - Drug Therapy
(24)
Biological And Medical Sciences
(20)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Structure-Based Discovery of Novel Ligands for the Orexin 2 Receptor

Comparative Docking to Distinct G Protein-Coupled Receptor Conformations Exclusively Yields Ligands with Agonist Efficacy

EP4 Receptor Conformation Sensor Suited for Ligand Screening and Imaging of Extracellular Prostaglandins

The Isoleucine at Position 118 in Transmembrane 2 Is Responsible for the Selectivity of Xamoterol, Nebivolol, and ICI89406 for the Human β 1-Adrenoceptor

Three stories on Eph kinase inhibitors: From in silico discovery to in vivo validation

Structure-based tailoring of compound libraries for high-throughput screening: Discovery of novel EphB4 kinase inhibitors

Direct targeting of Gα q and Gα 11 oncoproteins in cancer cells

Disentangling bias between G q , GRK2, and arrestin3 recruitment to the M 3 muscarinic acetylcholine receptor

Discovery of Cell-Permeable Non-Peptide Inhibitors of β-Secretase by High-Throughput Docking and Continuum Electrostatics Calculations

Insulin-like growth factor 1 receptor and response to anti-IGF1R antibody therapy in osteosarcoma

The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models

Smad3-dependent and -independent pathways are involved in peritoneal membrane injury

Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models

Defective DNA damage repair leads to frequent catastrophic genomic events in murine and human tumors

Plant fertilization interacts with life history: variation in stoichiometry and performance in nettle-feeding butterflies

PNPLA1 Deficiency in Mice and Humans Leads to a Defect in the Synthesis of Omega-O-Acylceramides

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program

Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report

Ecological stoichiometry and density responses of plant-arthropod communities on cormorant nesting islands

The pediatric preclinical testing program: Description of models and early testing results

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673

Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program

VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

Dose‐response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortium

Aktive Filter

Suchergebnisse filtern